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Abstract
Background: Anesthetic preconditioning can improve survival of cardiac progenitor cells exposed to oxidative
stress. We investigated the role of protein kinase C and isoform protein kinase C-ε in isoflurane-induced preconditioning
of cardiac progenitor cells exposed to oxidative stress.
Methods: Cardiac progenitor cells were obtained from undifferentiated human embryonic stem cells. Immunostaining
with anti-Nkx2.5 was used to confirm the differentiated cardiac progenitor cells. Oxidative stress was induced by H2O2
and FeSO4. For anesthetic preconditioning, cardiac progenitor cells were exposed to 0.25, 0.5, and 1.0 mM of isoflurane.
PMA and chelerythrine were used for protein kinase C activation and inhibition, while εψRACK and εV1-2 were used for
protein kinase C -ε activation and inhibition, respectively.
Results: Isoflurane-preconditioning decreased the death rate of Cardiac progenitor cells exposed to oxidative stress
(death rates isoflurane 0.5 mM 12.7 ± 9.3 %, 1.0 mM 12.0 ± 7.7 % vs. control 31.4 ± 10.2 %). Inhibitors of both protein
kinase C and protein kinase C -ε abolished the preconditioning effect of isoflurane 0.5 mM (death rates 27.6 ± 13.5 %
and 25.9 ± 8.7 % respectively), and activators of both protein kinase C and protein kinase C - ε had protective effects
from oxidative stress (death rates 16.0 ± 3.2 % and 10.6 ± 3.8 % respectively).
Conclusions: Both PKC and PKC-ε are involved in isoflurane-induced preconditioning of human embryonic
stem cells -derived Nkx2.5+ Cardiac progenitor cells under oxidative stress.
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Background
The heart is one of the least regenerative organs and ir-
reversible damage to a large amount of cardiomyocytes
may result in heart failure. There have been numerous
works on cardiac stem cell therapy for the regeneration
of damaged myocardium, however the results have been
controversial [1, 2]. Various types of stem cells originat-
ing from both embryonic and adult human tissue
sources were used for cardiac cell regeneration therapy.
For example, stem cell populations such as human em-
bryonic stem cells (hESCs), cardiac progenitor cells
(CPCs), bone marrow-derived stem cells, tissue specific
stem cells, and induced pluripotent stem cells have been
studied for cardiac repair [1]. Each cell type had its own
strengths and weaknesses and no single cell type has
been proven to meet the criteria for clinical applications.
CPCs hold promise for cardiac regeneration, and are
known to be multipotent and proliferative, and able to
differentiate into cardiomyocytes and vascular cells [3].
However, improving the graft survival in a hostile, dis-
eased environment such as ischemic myocardium is an
important issue to be resolved. For boosting the survival
rates of implanted CPCs to the infarcted heart,
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prosurvival cocktails were used, which had a mechanism
similar to anesthetic-induced preconditioning (APC) [4].
In APC, volatile anesthetics are known to have a protect-
ive effect in ischemia-reperfusion injury of myocardium. By
exposing the cells to volatile anesthetics before transplant-
ation, we expect the cells to have a greater survival rate
when transplanted into a poor ischemic environment. In
another study, we have shown that isoflurane has a precon-
ditioning effect in hESCs-derived CPCs, when applied
before exposure to oxidative stress [5].
Research has revealed that mitochondria, reactive oxy-
gen species, KATP channels, and protein kinase C (PKC)
play a major role in the mechanism of APC [6]. How-
ever, most of the studies on the mechanism of APC have
been with animals and data from human cells are scarce.
Additionally the determination of the exact isoform of
PKC which has the main role in APC was controversial.
In this study, we investigated the involvement of PKC
and more specifically, of isoform epsilon PKC (PKC-ε) in
isoflurane induced preconditioning of hESCs-derived
CPCs exposed to oxidative stress because PKC-ε was
shown to have a constant important role related to
ischemia- or anesthesia-induced preconditioning of ani-
mal experiments [2, 7–9].
Methods
hESCs culture, generation of hESCs-derived CPCs and
characterization of differentiated CPCs
The methods for hESCs culture, the generation of
hESCs-derived CPCs and characterization of differenti-
ated CPCs were the same as those of previous studies
[5, 10, 11]. This study did not include personal infor-
mation because human embryonic stem cells were
obtained from the National Stem Cell Bank. Institu-
tional review board of Institute of Reproductive Medicine
and Population approval was obtained (number: IRMP-
IRB2009112) and individual patient consent was waived as
there were no specific human participants.
In brief, H1 hESC (WA01) was cultured on a feeder
cell layer of mouse embryonic fibroblasts inactivated
with mitomycin C (Invitrogen, Carlsbad, CA, USA). Col-
onies of hESCs were passaged every week by a mechan-
ical micro-dissection method. After 60 % of the plates
were covered with undifferentiated cell colonies for over
7 days, the cells were made into small clumps with incu-
bation in the collagenase solution. They were then
moved to suspension culture in a 24-well non-treated
dish with a differentiation medium and were soaked for
4 days until the cells became embryoid bodies (EBs). A
total of 20 ng/ml of bone morphogenetic protein 4
(R&D Systems, Minneapolis, MN, USA) was mixed with
the differentiation medium for the suspension culture.
The EBs were moved into Matrigel-coated 35-mm plates
(BD Biosciences, San Jose, CA, USA) and expanded for
2–3 weeks. Immunostaining with antibodies directed
against human Nkx2.5 (mouse monoclonal, R&D Sys-
tems) was done to detect differentiated CPCs. 4, 6-
diamidino-2-phenylindole, DAPI (Vector Laboratories,
Burlingame, CA, USA) was used to stain all nuclei.
DAPI-positive cells were counted as the total number of
cells and the number of Nkx2.5-positive cells was
expressed as a percentage of the total number of cells.
The images from 10 random microscopic fields of each
plate at × 200 magnification were obtained.
Cell survival study
A cell survival study was performed using a previously re-
ported protocol [5, 12]. The differences were the drugs for
the experiments. The protocols for the experiments are il-
lustrated in Fig. 1. In brief, differentiated CPC clusters were
separated with 0.25 % of trypsin-ethylenediaminetetraacetic
acid solution for 5 min and were washed in the differenti-
ation medium. Several drops of suspension including CPCs
were placed in a chamber on the stage of an inverted
microscope (ECLIPSE TS100; Nikon, Tokyo, Japan) until
cells were settled. We stained those with 0.5 ml of 0.4 %
trypan blue solution (Sigma-Aldrich, St. Louis, MO, USA)
for 2 min followed by washout with glucose-free Tyrode
solution (132 mM NaCl, 10 mM, HEPES, 5 mM KCl,
1 mM CaCl2 and 1.2 mM MgCl2 adjusted to pH 7.4).
Round cells that excluded trypan blue were considered liv-
ing. We checked the location of living cells by a chamber
bottom with a labelled grid. Approximately one hundred
living CPCs were counted for 10 min in each experiment.
For example, N=7 refers to the counting the numbers of
about 700 living CPCs. After the cell count, the plate was
washed with glucose-free Tyrode for 30 min, then the CPCs
were exposed to 200 mM H2O2 and 100 mM FeSO4 ·
7H2O (Sigma-Aldrich) for 20 min to simulate the oxidative
stress. The CPCs were washed out with glucose-free Tyrode
solution for 20 min. Then the remaining living CPCs were
counted after staining with trypan blue. For APC, the cells
were exposed to isoflurane dissolved Tyrode solution for
20 min before exposure to the oxidative stress. We changed
all materials with a potential to contact CPCs such as plas-
tic tubing, plastic syringes, cover glasses and slide glasses to
new ones in every experiment to prevent contamination be-
tween treatment groups. Moreover we randomized the
order of experiments daily and the researchers who
counted the cell deaths with a microscope were blinded re-
garding drug treatment.
Drugs
Isoflurane was prepared by the same method as described
in the previous study [5]. Briefly, it was dissolved in
glucose-free Tyrode solution by sonication and delivered
to CPCs by airtight syringes. We exposed CPCs to
0.25 mM, 0.5 mM and 1.0 mM isoflurane. To confirm the
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concentrations of isoflurane which varied ± 10 % of the re-
ported value, analyses were performed by gas chromatog-
raphy (Shimadzu, Kyoto, Japan).
A PKC-ε inhibitor, cell permeable PKC-ε V1-2 peptide
(εV1-2) and a selective PKC-ε activator, pseudo-receptors
for activated C-kinase epsilon (εψRACK) were kindly pro-
vided gratis by the laboratory of Daria Mochly-Rosen (De-
partment of Chemical and Systems Biology, Stanford
University, CA). We dissolved an isoform-nonspecific
PKC inhibitor, chelerythrine (1 μM; Sigma-Aldrich), and
εV1-2 (1 μM) in the superfusing solution during oxidative
stress to examine the effects of the PKC and PKC-ε on cell
survival [13]. An isoform-nonspecific PKC activator, 4β-
phorbol 12-myristate 13-acetate (PMA, 10 nM) and a se-
lective PKC-ε activator, pseudo-receptors for activated C-
kinase epsilon (εψRACK, 2 μM) were mixed with the
superfusion solution for oxidative stress to illuminate the
effects of the PKC and their isoform on cell survival. PMA
was dissolved in dimethyl sulfoxide and εψRACK was dis-
solved in deionized distilled water. All stock solutions
were diluted to the required concentrations in the super-
fusing buffer immediately before usage.
Statistical analysis
N is the number of hESC-derived CPCs plates. Experi-
mental groups consisted of hESC-derived CPCs from at
least five separate differentiations. Predictive Analytics
Software statistics version 18.0 (SPSS Inc., Chicago, IL,
USA) was used for the statistical analyses. Data were an-
alyzed using one-way analysis of variance with the
Scheffé post hoc test. Differences were considered to be
statistically significant if P- values were less than 0.05.
Results are presented as means ± standard deviation.
Results
Differentiation and characterization of hESC-derived CPCs
Confocal microscopic examinations were done with five
plates to identify CPCs derived from hESCs with early car-
diac marker (Nkx2.5). The proportion of the cells stained
with Nkx2.5 was 95 ± 3 % of the total cell number (Fig. 2).
Isoflurane-induced preconditioning on hESC-derived CPCs
under oxidative stress
Glucose-free Tyrode solution did not have an effect on the
death rate of CPCs in the time-control group (9.6 ± 5.4 %,
n = 7). Oxidative stress increased the CPCs death rate to
31.4 ± 10.2 % (n = 11). For the evaluation of the precondi-
tioning effect of isoflurane, three concentrations were
used. Preconditioning with 0.25 mM of isoflurane did not
lower the death rate of CPCs (36.7 ± 18.0 %, n = 10). How-
ever, 0.5 mM and 1.0 mM of isoflurane decreased CPCs
death rate to 12.7 ± 9.3 % (n = 7) and 12.0 ± 7.7 % (n = 7)
respectively without a significant difference between the
two concentrations (Fig. 3).
Time control TYR (70 min)








H2O2 + FeSO4 (20 min) TYR (20 min)
Drug TYR + Drug (70 min)
Stress + Drug TYR (30 min)
H2O2 + FeSO4 + Drug 
(20 min)
TYR (20 min)







H2O2 + FeSO4 + Drug 
(20 min)
TYR (20 min)
Fig. 1 Schematic illustration of the study protocol. TYR = perfusion with Tyrode solution; Drug = chelerythrine or cell-permeable ePKC V1-2 pep-
tide (εV1-2) or 4β-phorbol 12-myristate 13-acetate (PMA) or pseudo-receptors for activated C-kinase epsilon (εψRACK)
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The involvement of PKC in isoflurane-induced precondi-
tioning on hESC-derived CPCs under oxidative stress
PMA and chelerythrine themselves had no effect on the
death rate of CPCs in the time-control groups (11.7 ±
5.9 %, n = 7 and, 8.9 ± 3.8 %, n = 7). PMA had a protective
effect on CPCs when they were under oxidative stress: the
death rates of CPCs were 16.0 ± 3.2 % (n = 8). When CPCs
were treated with PMA and 0.5 mM of isoflurane, PMA
did not reduce or potentiate the protective effect of isoflur-
ane (12.7 ± 7.0 %, n = 7) (Fig. 4a). Chelerythrine did not
show additional effects on the death rate of CPCs under
oxidative stress (24.1 ± 6.1 %, n = 8). However, it abolished
the preconditioning effects of isoflurane on CPCs under
oxidative stress (27.6 ± 13.5 %, n = 13) (Fig. 4b).
The involvement of PKC-ε in isoflurane-induced precondi-
tioning on hESC-derived CPCs under oxidative stress
There were no significant effects on the death rate of
CPCs by εψRACK and εV1-2 themselves in the time-
control group (7.8 ± 2.4 %, n = 8, and 12.8 ± 5.7 %, n = 8).
εψRACK had a protective effect on CPCs when they
were under oxidative stress: the death rates of CPCs
were 10.6 ± 3.6 % (n = 8). When εψRACK was added
after isoflurane wash out, it did not reduce or potentiate
the protective effect of 0.5 mM of isoflurane (7.8 ± 3.7 %,
n = 7) (Fig. 5a). εV1-2 did not show additional effects on
the death rate of CPCs when they were under oxidative
stress (25.2 ± 8.0 %, n = 8). However, it abolished the pre-
conditioning effect of isoflurane on CPCs under oxida-
tive stress (25.9 ± 8.7 %, n = 8) (Fig. 5b).
Discussion
This is, to our knowledge, the first study showing the in-
volvement of PKC and PKC-ε in APC using human cells.
Our data showed that PKC, and specifically PKC-ε in-
volved in isoflurane-induced preconditioning of hESCs-
derived Nkx2.5+ CPCs under oxidative stress because
the inhibitors of PKC and PKC-ε both abolished the pre-
conditioning effect of isoflurane and the activators of
both PKC and PKC-ε showed the protection of hESCs-
derived Nkx2.5+ CPCs from oxidative stress.
PKC seemed to play an important role in ischemic
preconditioning (IPC), with cardioprotection effect after
short ischemia-reperfusion injury. However PKCs have
at least 12 isoforms and the exact roles of each isoform
in ischemic preconditioning are not fully elucidated and
could well differ in studies using different animal species
and materials [14]. For example, PKC-ε and –δ in rats,
PKC-α in a canine model, PKC-α and –ε in adult human
right atrial appendage harvested from open heart surger-
ies, are known to play an essential role in IPC [14–17].
Certain isoforms, like PKC-δ, are known to act contrar-
ily in ischemic preconditioning. That is, inhibiting PKC-
δ showed cardioprotection from simulated ischemia in
rat and mouse [18].
Fig. 2 Immunostaining with DAPI, and anti-Nkx2.5 was performed to confirm cardiac differentiation of human embryonic stem cells. The merge




















Fig. 3 Effect of isoflurane-induced preconditioning on death rate of
hESCs-derived Nkx2.5+ CPCs under oxidative stress. Preconditioning
with 0.25 mM of isoflurane could not lower the death rate of CPCs
under oxidative stress. However, preconditioning with 0.5 mM and
1.0 mM of isoflurane decreased death rate of CPCs. * Statistically
significant differences with group time control, group Iso 0.5 + str,
and group Iso 1.0 + str (P < 0.05). Each black bar represents the 95 %
confidence interval and a black diamond the mean value of the
death rate of CPCs. Iso 0.25 + Str = 0.25 mM of isoflurane plus stress;
0.5 Iso + Str = 0.5 mM of isoflurane plus stress; 1.0 Iso + Str = 1.0 mM
of isoflurane plus stress
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APC seems to be a novel method of cardioprotection
from ischemic injury which could be done safely without
risk of myocardial ischemia, which was a weak point of
IPC. It may be equally as effective as IPC and have some
mechanisms in common with IPC, as we showed both
previously and in this study with isoflurane-induced
APC [5, 6].
Although the mechanism of APC has been studied, it is
still not clear enough. The keynote of the mechanism of
APC might be in the mitochondria as the end effecters of
ischemia and reperfusion injury and as the determinant of
cell death. That is, the opening of mitochondrial perme-
ability transition pores permit cellular Ca2+ overload and



































Fig. 4 The role of PKC on 0.5 mM of isoflurane-induced preconditioning
of hESCs-derived Nkx2.5+ CPCs under oxidative stress. a 4β-phorbol 12-
myristate 13-acetate (PMA), an isoform-nonspecific PKC activator, induced
the effect of preconditioning. * Statistically significant differences
with group time control, group Iso + str, group str + PMA, and
group Iso + str + PMA (P< 0.05). b Chelerythrine, an isoform-nonspecific
PKC inhibitor, abolished the preconditioning effect of isoflurane.
* Statistically significant differences with group time control,
and group Iso + str (P < 0.05). Each error bar represents the
95 % confidence interval and a diamond indicates the mean
value of the death rate of CPCs. Iso + Str = isoflurane plus stress;
Str + Chel = stress plus chelerythrine; Iso + Str + Chel = isoflurane
plus stress Chelerythrine; Str + PMA = stress plus PMA; Iso + Str +


































Fig. 5 The role of PKC-ε on 0.5 mM of isoflurane-induced
preconditioning of hESCs-derived Nkx2.5+ CPCs under oxidative
stress. a εψRACK, a selective PKC-ε activator, induced the effect
of preconditioning. * Statistically significant differences with
group time control, group Iso + str, group str + εψRACK, and
group Iso + str + εψRACK (P < 0.05). b a cell-permeable epsilon
PKC V1-2 peptide (εV1-2), a selective PKC-ε inhibitor, abolished the
preconditioning effect of isoflurane. * Statistically significant differences
with group time control, and group Iso + str (P< 0.05). Each error bar
shows the 95 % confidence interval and a diamond denotes the mean
value of the death rate of CPCs. Iso + Str = isoflurane plus stress; Str
+ εV1-2 = stress plus εV1-2; Iso + Str + εV1-2 = isoflurane plus stress εV1-2;
Str + εψRACK = stress plus εψRACK; Iso + Str + εψRACK = isoflurane plus
stress εψRACK
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might delay the opening of mitochondrial permeability
transition pores via PKC-ε mediated inhibition in rat myo-
cardium [20]. Current study also implied that PKC- ε also
involved in the APC mechanism of humans.
We used hESCs which could differentiate into various
cells, including cardiomyocytes, and can play an important
role in pathophysiologic or pharmacologic studies on car-
diac disease. Indeed, these hESC-derived cardiomyocytes
make action potential, utilize calcium rendering it transi-
ent and show excitation-contraction coupling [21, 22].
The hESC-derived cardiomyocytes were transplanted
to treat infarcted rat heart but the results are controver-
sial [4, 23]. The efficacy of transplanted hESC-derived
cardiomyocytes depended on the ability to survive in the
poor environment of the host. CPCs could also be used
for transplantation and show a higher survival rate after
transplantation than cardiomyocytes. The microenviron-
ment of transplanted cells could provide cues for further
differentiation into mature cells such as vascular smooth
muscle cells, endothelial cells or cardiomyocytes [24].
There were clinical trials using CPCs after myocardial
infarction showing improvement of myocardial function
or the reduction of the scar mass with increase of
regional contractility and with no adverse effect until
6 months or 1 year [25, 26]. Our results might contrib-
ute to a method of improving the survival of CPCs
engrafted to a hostile environment thus increasing the
success rate of cardiac regeneration therapy.
Limitations
Our data showed the possibilities of using the activator
of PKC or PKC-ε instead of preconditioning by artifi-
cially inducing ischemia or by exposure to anesthetics
for the prevention of ischemic injury, making the pro-
cedure more convenient by simple injection of drugs.
However, the study hinges on the specificity of the PKC
inhibitors and activators, and is largely pharmacologic
in nature. The lack of control peptides is a limitation.
The safety of the drugs should be elucidated further
before clinical application. For example, PMA, a non-
specific PKC activator is known to be a carcinogen
[27]. In addition, nonspecific activators of PKC should
be used with caution, although our data showed pro-
tective effects, because some of isoforms are known to
have the opposite effects [18]. Accordingly PKC-ε acti-
vator like εψRACK might be a promising choice in this
aspect, however further evaluation concerning efficacy
and toxicity in human beings is also required. Another
limitation was whether the study with hESCs could
reflect the situation of the real human hearts in vivo as
this study was exclusively performed in tissue culture
experiments, which is required for future studies in the
clinical setting.
Conclusions
Both PKC and PKC-ε might be involved in isoflurane-
induced preconditioning of hESCs-derived Nkx2.5+ CPCs
under oxidative stress.
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